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Although in vivo animal models exist for many clinically rel-evant and emerging human pathogens1–4, they currently all lack biologically relevant human cells, which limits our abil-
ity to study pathogen replication, pathogenesis, immune responses 
and sensitivity to therapeutics in vivo. In vivo animal models with 
natural human target cells for infection are needed to accelerate 
the development and testing of effective vaccines and therapeutics 
for many highly relevant human pathogens such as human cyto-
megalovirus (HCMV), human respiratory syncytial virus (RSV) and 
Mycobacterium tuberculosis, in addition to many emerging patho-
gens1, all of which cause substantial global mortality and morbidity5–9.
Although commonly used, inbred mouse strains do not faith-
fully recapitulate important aspects of human disease and the 
human immune response10. Furthermore, many human pathogens 
do not replicate in wild-type mice1,5,11–21. The availability of highly 
immunodeficient mouse strains allows for the creation of human/
mouse chimeric models (humanized mice) that are locally or sys-
temically reconstituted with human hematopoietic cells follow-
ing engraftment of human tissues and/or stem cells. Humanized 
mice have been used to study human immune development and 
human-specific pathogens that replicate in human hematopoietic 
cells (for example, Epstein–Barr virus, dengue virus, human immu-
nodeficiency virus, Kaposi’s sarcoma herpesvirus) and to test the 
efficacy of preventative and therapeutic agents5,11–19,22,23. Bone mar-
row/liver/thymus (BLT) humanized mice are generated by bone 
marrow transplantation of immunodeficient mice implanted with 
autologous human thymus/liver tissue. BLT mice are systemically 
reconstituted with human innate (monocytes/macrophages, den-
dritic cells, natural killer (NK) cells) and adaptive (B and T cells) 
immune cells. The presence of a human thymic organoid in the BLT 
model allows for human T-cell education on human leukocyte anti-
gens (HLA) and the induction of HLA-restricted T-cell responses 
consistent with those observed in humans14,24,25.
The applications of current humanized mouse models for bio-
medical research would be significantly broadened by the inclusion 
of human nonhematopoietic cell types, the primary targets of most 
human pathogens, which can present antigen to autologous human 
immune cells in the full context of HLA5,9,26–29. The human lung 
contains up to 40 different cell types including epithelial, endothe-
lial, mesenchymal and smooth muscle cells30 and it is an important 
natural site of pathogen replication9,26,31–34. We implanted human 
lung tissue subcutaneously into the back of immunodeficient mice 
to create humanized lung-only mice (LoM). The human lung 
tissue vascularizes, expands and persists as a human lung implant, 
and supports replication of viral and bacterial human pathogens 
in  vivo. When incorporated into BLT mice (BLT-lung (BLT-L) 
mice), lung implants are repopulated with autologous human innate 
and adaptive immune cells. Direct inoculation of BLT-L human 
lung implants with HCMV induces HCMV-specific human IgM, 
IgG and T-cell responses which can effectively control infection 
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A major limitation of current humanized mouse models is that they primarily enable the analysis of human-specific pathogens 
that infect hematopoietic cells. However, most human pathogens target other cell types, including epithelial, endothelial and 
mesenchymal cells. Here, we show that implantation of human lung tissue, which contains up to 40 cell types, including non-
hematopoietic cells, into immunodeficient mice (lung-only mice) resulted in the development of a highly vascularized lung 
implant. We demonstrate that emerging and clinically relevant human pathogens such as Middle East respiratory syndrome 
coronavirus, Zika virus, respiratory syncytial virus and cytomegalovirus replicate in vivo in these lung implants. When incorpo-
rated into bone marrow/liver/thymus humanized mice, lung implants are repopulated with autologous human hematopoietic 
cells. We show robust antigen-specific humoral and T-cell responses following cytomegalovirus infection that control virus 
replication. Lung-only mice and bone marrow/liver/thymus-lung humanized mice substantially increase the number of human 
pathogens that can be studied in vivo, facilitating the in vivo testing of therapeutics.
in vivo. LoM and BLT-L mice expand the susceptibility of human-
ized mice to a broad range of human pathogens. These models can 
be used to study pathogen replication, pathogenesis, immune reac-
tivity and human therapies.
Results
Human lung tissue development into ectopic lung implants. 
Two small pieces of human lung tissue were surgically implanted 
into separate sites on the back of immunodeficient mice to cre-
ate humanized LoM. Over time, the implanted tissue expanded 
(Fig. 1a). B-mode ultrasound imaging established the presence of 
well-defined implants with a mean volume of 0.75 cm3 (±0.42 cm3) 
(Fig. 1b,c). Acoustic angiography35,36 revealed angiogenesis and the 
formation of large blood vessels (Fig. 1d, left panel). Vasculature 
was also observed within the human lung implant (Fig. 1d, right 
panel). Figure 1e and Supplementary Video 1 show a three-dimen-
sional (3D) reconstruction of the implant, illustrating its structure 
and extensive vasculature. Finally, surgical excision of a human 
lung implant revealed its well-defined structure and internal vas-
culature (Fig. 1f).
Even though the lung implants are ectopic and not ventilated, 
we observed structures that are characteristic of the human lung 
including airways, ciliated epithelium, alveolar structures, cartilage 
and associated blood vessels (Fig. 1g). We observed cartilaginous 
bronchial and noncartilaginous bronchiolar airways, both of which 
were lined by ciliated airway epithelium (Fig. 1g). Pre-alveolar 
sacs were also present (Fig. 1g). The presence of human epithelial, 
endothelial and mesenchymal cells was also confirmed (Fig. 1h,i). 
Club cells and nonciliated secretory epithelial cells were also pres-
ent (Fig. 1j). Staining for mucus secretions revealed the presence 
of mucin-secreting human globlet epithelial cells (Fig. 1k). Ex vivo 
culture of lung implant cells with lipopolysaccharide (LPS) demon-
strated their capacity to produce human cytokines and chemokines 
(Supplementary Table 1).
Analysis of human donor matched lung tissue at the time of 
implantation and at 2 months postimplantation indicates continuous 
human lung tissue development. Pre-alveolar sacs were expanded 
and both flattened and cuboidal-shaped epithelial cells could be 
observed in alveoli, indicative of type I and type II pneumocytes, 
respectively (Supplementary Fig. 1). Although not observed in lung 
tissue at the time of implantation, club cells were readily detected 
2 months later (Fig. 1j and Supplementary Fig. 1) and ciliated 
epithelial cells were more abundant (Supplementary Fig. 1).
Consistent with reports of other subcutaneously implanted 
human tissues (for example, synovial tissue and bone)37,38, the vas-
culature within the human lung implants is primarily of human ori-
gin (Fig. 1h). Mouse endothelial and epithelial cells were not readily 
detected (Supplementary Fig. 2). Few hematopoietic cells (murine or 
human) could be detected in human lung implants (Supplementary 
Figs. 2 and 3). In summary, implantation of human lung tissue into 
the back of immunodeficient mice results in the development of 
well-defined, well-vascularized and easily accessible human lung 
implants with structures that resemble those present in human lung 
tissue and that are composed almost entirely of human cells.
LoM support infection of a broad range of human pathogens. 
Middle East respiratory syndrome coronavirus (MERS-CoV) is an 
emerging human pathogen that targets the human lung26 but which 
does not infect mice, ferrets or hamsters due to genetic differences 
in its receptor, dipeptidyl peptidase 4 (DPP4)1,20,21. MERS-CoV was 
inoculated directly into the human lung implants of LoM. MERS-
CoV titers (mean 2.02 × 108 ± 1.08 × 108 s.e.m. plaque-forming 
units (PFU) ml−1 g−1; range 1.2 × 106–8.09 × 108 PFU ml−1 g−1) in the 
human lung implants 48 h later were 3 logs higher than the inoculum 
(Fig. 2a). The presence of MERS-CoV antigen in human epithe-
lial, endothelial and mesenchymal cells indicated that MERS-CoV 
has broad cellular tropism in vivo (Fig. 2b). At a lower inoculum 
(104 PFU), MERS-CoV replication was variable but still read-
ily detectable (mean 2.29 × 108 ± 2.09 × 108 s.e.m. PFU ml−1 g−1; 
range1.92 × 103–8.57 × 108 PFU ml−1 g−1) (Fig. 2a).
Zika virus (ZIKV) has been detected in human neonatal lungs 
and shown to infect human lung cell lines in vitro31,39. In wild-type 
mice, the type 1 interferon response suppresses ZIKV infection2. 
Human lung implants of LoM inoculated with ZIKV and assayed 
48 h later contained robust levels of cell-associated ZIKV RNA 
(mean 1.37 × 104 ± 5.91 × 103 s.e.m. ZIKV RNA copies per 105 cells; 
range 5.21 × 103–2.42 × 104 ZIKV RNA copies per 105 cells) (Fig. 2c). 
ZIKV antigen was detected in human epithelial and mesenchy-
mal cells (Fig. 2d). Similar to MERS-CoV, at a lower inoculum 
(103 focus-forming units (FFU)), ZIKV RNA levels were variable 
but readily detectable (mean 2.65 × 103 ± 1.47 × 103 s.e.m. ZIKV 
RNA copies per 105 cells; range 2.7 × 101–6.83 × 103 ZIKV RNA cop-
ies per 105 cells) (Fig. 2c).
We inoculated Mycobacterium bovis Bacillus Calmette-Guérin 
(BCG), the attenuated live vaccine strain of M. tuberculosis, into 
the human lung implants of LoM. Bacterial burden was assessed 
by colony formation (colony forming units, c.f.u.). BCG levels 
in human lung implants of LoM 28 d postexposure (mean 
3.40 × 105 ± 1.20 × 105 s.e.m. c.f.u.; range 1.03 × 105–4.95 × 105 
c.f.u.) were 8.5-fold higher than the inoculum (4 × 104 c.f.u.)
(Fig. 2e). BCG also replicated in the human lung implants of LoM
receiving a 100-fold lower inoculum (4 × 102 c.f.u.); the bacterial
burden (mean 2.57 × 104 ± 1.53 × 104 s.e.m. c.f.u.; range 3.10 × 103–
5.49 × 104 c.f.u.) was 65-fold higher than the inoculum. Acid-fast
staining confirmed diffuse clusters of bacteria within the human
lung implants (Fig. 2f).
We inoculated LoM implants with RSV expressing green fluo-
rescent protein (GFP). At 4 d post-RSV inoculation, GFP-positive 
cells indicative of RSV infection and replication were detected in 
the human lung implants (mean 144.38 ± 41.53 s.e.m. GFP+ cells 
per 105 total cells; range 35–333 GFP+ cells per 105 total cells) 
(Fig. 2g). Infection of human airway epithelial cells in vitro and 
in  vivo with RSV is characterized by extrusion of infected cells 
into the airway lumen and loss of cilia from infected ciliated 
cells40. Consistent with these observations, RSV-infected cells 
were observed protruding and shedding from the epithelial cell 
layer into the lumen (Fig. 2h) and they lacked costaining for cilia 
(Fig. 2i). Large deposits of mucin were also noted in the airways of 
RSV-infected lung implants (Fig. 2j) as has been observed in the 
lungs of RSV-infected children41.
HCMV is a ubiquitous human-specific pathogen that does not 
replicate in other species5. We injected cell-free HCMV TB40/E, a 
clinical HCMV strain, into the human lung implants of LoM. HCMV 
DNA was detected in the lung implants of LoM as early as 4 d post-
inoculation (mean 4.70 × 103 ± 2.54 × 103 s.e.m. HCMV DNA copies 
per 105 cells; range 2.94 × 102–1.19 × 104 HCMV DNA copies per 105 
cells) (Fig. 2k). HCMV immediate early (IE), early and late proteins 
were detected in lung implants at 14 d and 52 d postinoculation 
indicating that HCMV infection was maintained over time (Fig. 2l). 
The expression of IE proteins is consistent with lytic HCMV repli-
cation in this model as observed during human primary infection 
and reactivation42. In vivo, HCMV antigen was observed in human 
mesenchymal cells (Fig. 2m). We determined the effect of pre-
exposure prophylaxis with ganciclovir (GCV) on HCMV replica-
tion in LoM. GCV was administered once daily 2 d before and 14 d 
after inoculation of HCMV TB40/E expressing luciferase (Fig. 2n). 
HCMV replication was monitored over time by measuring lucif-
erase activity. By 4 d postexposure, HCMV levels were ~66% 
lower in the human lung implants of GCV-treated LoM (mean 
3.36 × 105 ± 1.61 × 105 s.e.m. radiance) compared with untreated 
controls (mean 1.00 × 106 ± 2.90 × 105 s.e.m. radiance) (Fig. 2n). 
HCMV levels continued to decline over time in GCV-treated LoM. 
At the end of the GCV treatment course (14 d post-HCMV expo-
sure), HCMV levels were ~2 logs lower in the lung implants of 
GCV-treated LoM (mean 1.48 × 105 ± 4.96 × 104 s.e.m. radiance) 
compared with untreated LoM (mean 8.99 × 106 ± 5.02 × 106 s.e.m. 
radiance) (Fig. 2n). Surprisingly, after GCV treatment was discon-
tinued, HCMV levels continued to decline. By 25 d post-HCMV 
exposure (11 d after the last GCV dose), HCMV levels in the lung 
implants of GCV-treated LoM were further reduced by ~40% (mean 
9.25 × 104 ± 2.65 × 104 s.e.m. radiance) and significantly lower than 
untreated controls (mean 3.27 × 107 ± 1.69 × 107 s.e.m. radiance) 
(Fig. 2n). Together, these results demonstrate the ability of LoM to 
sustain replication of several clinically relevant human pathogens 
and to serve as a platform for the in  vivo testing of existing and 
novel antimicrobials.
HCMV gene expression is consistent with lytic replication. In 
healthy individuals, HCMV establishes a life-long latent infection. 
In immune-suppressed individuals such as transplant and AIDS 
patients, HCMV can reactivate, resulting in uncontrolled lytic rep-
lication causing a multi-organ cytomegalovirus (CMV) syndrome43. 
Therefore, novel antivirals are needed that can inhibit HCMV lytic 
replication in vivo to ameliorate clinical symptoms of CMV disease. 
Since natural infections are typically asymptomatic and undiag-



























































Fig. 1 | Subcutaneous implantation of human lung tissue into immunodeficient mice results in the development of readily accessible ectopic human 
lung implants. a, Subcutaneous human lung implant (n = 1 LoM imaged, black arrow). b, B-mode ultrasound imaging of a human lung implant (blue circle) 
under the skin. c, Volume (cm3) of human lung implants (n = 12, filled circles) in mice determined from B-mode ultrasound images. d,e, In vivo visualization 
of human lung implant blood vessel vascularization by acoustic angiography (n = 12 implants analyzed). d, Acoustic angiography image showing blood 
vessels encapsulating (left) and within (right) a human lung implant. A red dashed line (left panel) indicates the location of the implant cross-section 
depicted in the right panel. e, 3D rendering of vascularization (red) of a human lung implant (blue). f, Gross structure of an excised human lung implant 
(n = 1) 2 months postsurgery exhibiting blood vessel vascularization (black arrows). g, Histologic sections of human lung implants (n = 6 implants 
analyzed) showing presence of airways, ciliated epithelium, alveolar structures, cartilage and associated blood vessels (images: top panel, ×5, bottom 
panels, ×100). h, Immunofluorescence staining for human epithelial, endothelial and mesenchymal cells in a human lung implant (n = 3 implants analyzed, 
left panels) and mouse lung (n = 1 mouse lung analyzed, right panels) (positive cells, red; nuclei, blue). i,j, Immunofluorescence staining for cytokeratin 
19 (magenta) and (i) cilia or (j) club cells (green; scale bars, 20 µm) in a human lung implant (n = 4 implants analyzed). k, AB-PAS staining for mucous 
secretions (blue; scale bars, 20 µm) in a human lung implant (n = 4 implants analyzed). In c, horizontal lines represent mean ± s.e.m. Scales bars in b and d, 
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Fig. 2 | LoM are susceptible to infection with a broad range of emerging and clinically relevant human pathogens. a, MERS-CoV titer in infected lung 
implants (105 PFU dose: n = 8, filled squares; 104 PFU dose: n = 4, open squares). b, MERS-CoV-infected cells (green) costained for human epithelial 
(cytokeratin 19), endothelial (CD34) or mesenchymal (vimentin) cell markers (magenta) in a lung implant (n = 1; images, ×40). c, ZIKV RNA copies in 
infected lung implants (104 FFU dose: n = 4, filled upward triangles; 103 FFU dose: n = 4, open upward triangles). d, ZIKV-infected cells (green) costained 
for human epithelial or mesenchymal cell markers (magenta) in a lung implant (n = 1; images, ×40). e,f, BCG c.f.u. (4 × 104 c.f.u. dose: n = 3, closed 
diamonds; 4 × 102 c.f.u. dose: n = 3, open diamonds) (e) and Ziehl–Neelsen acid-fast staining for BCG (positive, pink) (f) in lung implants (n = 2). Top and 
bottom images, ×100. g, Number of RSV-GFP positive cells in lung implants (n = 6, closed downward triangles). h, RSV-infected cells (green) costained 
for a human epithelial cell marker (magenta) in a lung implant (n = 1, image, ×40). i, Costaining for RSV-infected cells (green) and ciliated cells (magenta) 
(top) and isotype control antibody (green) and ciliated cells (magenta) (bottom panel) in a human lung implant (n = 4 analyzed; images, ×100). j, AB-PAS 
staining for mucus (blue) in a naïve control (n = 4 analyzed, top) and RSV-infected (n = 4 analyzed, bottom) lung implant (scale bars, 100 µm). k, HCMV 
DNA levels (open circles) in lung implants at 4 d (n = 4), 7 d (n = 4), 14 d (n = 5) and 21 d (n = 3) post-TB40/E exposure. l, HCMV IE, early (E) and late 
(L) protein expression in lung implants (n = 1 per time point; images, ×40; positive cells, brown). m, HCMV-infected cells (green) costained for a human 
mesenchymal cell marker (magenta) in a lung implant (n = 1; image, ×40). n, GCV was administered to LoM daily (100 mg kg−1) for 17 d starting 2 d before 
HCMV TB40/E exposure. HCMV-luciferase activity in lung implants of GCV-treated LoM (orange boxes; n = 6) and untreated control LoM (white boxes; 
days 4–21, n = 7 and day 25, n = 6) was compared with a two-tailed Mann–Whitney test. The median (horizontal line), upper and lower quartiles (box 
ends), and minimum to maximum values (whiskers) are shown. In a–k, n = number of lung implants analyzed and horizontal lines represent mean ± s.e.m. 
In b, d, f, h, i, l and m, scale bars shown for ×40 (50 µm) and ×100 (20 µm) images. In b, d, h and m, the bottom left inset image represents the area 
indicated with a dashed box and nuclei are stained blue. H, human; LNG, lung; p, photons.
in  vivo has not been determined on a genome-wide scale due to 
the difficulty of obtaining acutely infected samples. To define the 
complement of HCMV genes expressed in human tissue in vivo, we 
injected cell-free HCMV TB40/E into the human lung implants of 
LoM. HCMV double-stranded complementary DNA ((ds)cDNA) 
was enriched with biotinylated probes spanning both strands of 
the entire HCMV genome and next generation sequencing used to 
measure viral gene expression. Using this approach, we were able to 
measure the complement of viral genes expressed in vivo in human 
tissue during lytic replication. Results revealed widespread HCMV 
gene expression spanning the viral genome, consistent with robust 
lytic replication (Supplementary Fig. 4). Expression of known lytic 
genes encoding IE proteins IE1 (UL123) and IE2 (UL122), early 
proteins (UL44 and UL38), and late proteins pp65 (UL83) and pp71 
(UL82) were detected. By contrast, expression of UL138, a well-
characterized latency gene, was not observed. These results serve as 
proof-of-principle of the utility of LoM to investigate key aspects of 
HCMV replication in human lung tissue in vivo.
The human innate and adaptive immune system of BLT-L mice. 
We generated an in  vivo model with human lung implants and 
an autologous human immune system by constructing BLT mice 
with autologous human lung implants (BLT-L humanized mice). 
BLT-L mice were constructed by surgically implanting (1) autolo-
gous human thymus and liver tissue under the kidney capsule and 
(2) human lung tissue subcutaneously into the back of the same pre-
conditioned (irradiated) immunodeficient mouse followed by bone
marrow transplantation with autologous human hematopoietic
stem cells (Fig. 3a). Over time, BLT-L mice developed human lung 
implants and robust levels of human hematopoietic cells (hCD45+) 
in peripheral blood (PB) that were sustained for at least 8 months 
(last time analyzed) (Fig. 3b). The PB of BLT-L mice was reconsti-
tuted with human myeloid cells, B cells and T cells, including CD4+ 
and CD8+ T cells (Supplementary Fig. 5).
In addition to human epithelial, endothelial and mesenchy-
mal cells (Fig. 3c), human lung implants of BLT-L mice contained 
human innate and adaptive immune cells (Fig. 3d). Ex vivo stimula-
tion of these cells with phorbol myristate acetate (PMA)/ionomy-
cin or LPS demonstrated their broad capacity for human cytokine 
(pro-inflammatory and anti-inflammatory) and chemokine pro-
duction (Supplementary Table 2). The human hematopoietic cells 
present in the human lung implants of BLT-L mice (hCD45+, mean 
72.5% ± 5.5% s.e.m.; range 27.4–90.4%) included human myeloid 
cells (hCD33+, mean 15.2% ± 3.0% s.e.m.; range 0.5–42.8%), 
B cells (hCD19+, mean 7.5% ± 1.7% s.e.m.; range 0.4–22.2%) 
and T cells (hCD3+, mean 63.4% ± 4.6% s.e.m.; range 26.9–92.3%) 
(Fig. 3e). No significant difference in human myeloid cell, B-cell 
or T-cell levels was observed between the human lung implants 
and mouse lung of BLT-L mice (Supplementary Fig. 6). CD4+ and 
CD8+ human T cells were present in the human lung implants of 
BLT-L mice. Human CD4+ T-cell levels were significantly lower 
(P = 6.472 × 10–7) and CD8+ T-cell levels were significantly higher 
(P = 0.0004) in the human lung implants of BLT-L mice compared 
with the mouse lung. The CD4/CD8 T-cell ratio (mean 2.2 ± 0.17 
s.e.m.; range 0.93–3.42) in human lung implants (Fig. 3e) was simi-























































































































































Fig. 3 | Systemic reconstitution of BLt-L humanized mice with human innate and adaptive immune cells. a, Construction of BLT-L humanized mice.  
b, Human hematopoietic cells (hCD45+) in PB of BLT-L mice (n = 26 mice, 5 cohorts). Colors indicate BLT-L mouse cohorts. c, Immunofluorescence 
staining for human epithelial, endothelial and mesenchymal cells in a human lung implant of a BLT-L mouse (n = 4 mice analyzed; positive cells, red; 
nuclei, blue). Images shown are at ×10 magnification (scale bars, 50 µm). d, Human hematopoietic (hCD45) cells including dendritic cells (hCD11c), 
macrophages (hCD68), B cells (hCD20), NK/NK T cells (hCD56) and T cells (hCD3, hCD4 and hCD8) in the human lung implant (n = 3 mice analyzed; 
positive cells, brown). Images shown are at ×40 magnification (scale bars, 50 µm). e, Levels of hCD45 cells including human myeloid cells (hCD33), B 
cells (hCD19) and T cells (hCD3) as well as the ratio of human CD4/CD8 T cells in the human lung implants (open circles) of BLT-L mice (hCD45, hCD33 
and hCD3 analysis, n = 18 implants; and hCD19 and hCD4/CD8 analysis, n = 15 implants). f, Human CD45+ cells in tissues of BLT-L mice (n = 4 mice 
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Fig. 4 | HCMV infection induces robust, sustained humoral and t-cell responses that control virus replication in BLt-L mice. a, HCMV TB40/E-luciferase 
activity in lung implants of LoM (blue boxes; n = 6 implants) and BLT-L mice (yellow boxes; n = 6 implants). Baseline, luminescence measured pre-exposure. 
The median (horizontal line), upper and lower quartiles (box ends), and minimum to maximum values (whiskers) are shown. Two-tailed Mann–Whitney 
test. b, HCMV-specific IgM in the plasma of HCMV-exposed BLT-L mice (TB40/E: BLT-L5 and BLT-L6, ADrUL131: BLT-L 9) and five naïve control BLT-L 
mice. Mean values (horizontal lines) and technical replicates are shown for each mouse. Dashed line, threshold for seropositivity defined from naïve 
mice. c, HCMV-specific CD8+ T cells detected by pentamer-reactivity in the lung implant (H LNG) of one BLT-L mouse 12 d postexposure. d, Pentamer-
reactive HCMV-specific CD8+ T cells in the lung implant 21 d postexposure (left). Overlay of pentamer-reactive cells (red) on PMA/ionomycin-stimulated 
CD8+ T cells (gray) from one BLT-L mouse is shown (right). e, IFN-γ ELISpot reactivity to commonly targeted CD8+ T-cell epitopes in human infection. 
Mean values (horizontal lines) and technical replicates are shown for two BLT-L mice. f,g, IFN-γ ELISpot reactivity to the HCMV IE1 protein. Mean values 
(horizontal lines) and technical replicates are shown for six BLT-L mice. e–g, ELISpot data are background subtracted. Criteria for positivity: ≥2 x mean of 
replicate negative control wells and >50 SFU per million CD3+ T cells. h, IE1-specific IFN-γ+CD107a+ CD8+ T cells detected 125 d post-HCMV exposure 
in one BLT-L mouse. e–h, Cells were isolated from the liver (LIV) (e, f and h) or mouse lung (M LNG) (g). b–h, BLT-L cohorts are indicated in parentheses. 
c–h, BLT-L mice were exposed to HCMV strain TB40/E or AD169 as indicated. Full details of immune reactivity for each BLT-L mouse are indicated in 
Supplementary Tables 4 and 5. p, photons.
was observed (Supplementary Fig. 6). Memory (CD45RO+) CD4+ 
and CD8+ T cells were present in the human lung implants of BLT-L 
mice, the majority of which expressed an effector memory pheno-
type (CCR7-negative) (CD4+ T  cells, mean 87.2% ± 1.97% s.e.m.; 
range 81.8–90.8% and CD8+ T  cells, mean 97.1% ± 0.44% s.e.m.; 
range 96.1–97.9%) (Supplementary Fig. 7a,b). We also identified 
the presence of CD4+ (mean 25.4% ± 3.58% s.e.m.; range 18.5–
35.5% of memory CD4+ T cells) and CD8+ (mean 38.5% ± 7.11% 
s.e.m.; range 21.0–51.8% of memory CD8+ T cells) tissue-resident
memory T cells (CD45RO+CD69+) in the human lung implants of
BLT-L mice, as observed in humans (Supplementary Fig. 7c,d)44.
Similar to BLT mice, in addition to the human lung implant, human 
hematopoietic cells were systemically distributed throughout the
animals including primary and secondary immune tissues (bone
marrow, human thymic implant, spleen and lymph nodes), effec-
tor sites and mucosal tissues (lung, liver, gastrointestinal tract and
female reproductive tract) of BLT-L mice (Fig. 3f). Innate and
adaptive human immune cells were present in all tissues analyzed
(Supplementary Fig. 7e).
Immune-mediated control of HCMV infection in BLT-L mice. 
LoM and BLT-L mice were inoculated with HCMV TB40/E express-
ing luciferase45. HCMV replication was detectable in the human lung 
implants of LoM and BLT-L mice at 4 d postinoculation (Fig. 4a). 
In LoM, robust HCMV replication was maintained up to 5 weeks 
postinoculation (last time point analyzed) (Fig. 4a). In contrast, in 
BLT-L mice HCMV replication began to decline by 11 d postinocu-
lation (Fig. 4a). Luciferase activity in BLT-L mice was significantly 
lower compared with LoM (Fig. 4a). HCMV replication in BLT-L 
mice continued to decline over time (Fig. 4a). Specifically, luciferase 
activity in the human lung implants of BLT-L mice at week 4 (mean 
5.10 × 104 ± 2.25 × 104 s.e.m. radiance; range 2.68 × 104–8.4 × 104 
radiance) and week 5 (mean 6.46 × 104 ± 8.08 × 103 s.e.m. radiance; 
range 5.5 × 104–7.47 × 104 radiance) postinoculation approached 
baseline levels (mean 2.34 × 104 radiance) and was significantly 
lower compared with LoM (Fig. 4a). These results demonstrate that 
while the human lung implants of LoM and BLT-L mice support 
HCMV infection, in contrast to LoM, HCMV replication is effi-
ciently controlled in BLT-L mice.
Levels of human cytokines and chemokines were analyzed 
in BLT-L mice pre- and post-HCMV TB40/E inoculation. 
At 4 d postinoculation, increased plasma levels of human GM-CSF, 
IFN-γ, IL-6, IL-8, MDC, IP-10, GRO and MCP-1 were detected 
(Supplementary Fig. 8). HCMV-specific human antibody and T-cell 
responses were examined in BLT-L mice exposed to the three dif-
ferent HCMV strains: TB40/E, AD169 and ADrUL131. AD169 is 
a well-characterized fibroblast-adapted laboratory strain that lacks 
the UL131 gene. ADrUL131 is an AD169 derivative in which UL131 
is repaired46–48. PB plasma was collected longitudinally to measure 
HCMV-specific IgM levels. HCMV IgM levels in humans peak 
between 1 and 3 months after primary infection49. Consistent with 
human infection, HCMV IgM was detected as early as 14 d follow-
ing TB40/E or ADrUL131 inoculation in different BLT-L cohorts 
(that is, mice generated from different human donor tissues) 
(Fig. 4b and Supplementary Tables 3 and 4).
To examine whether BLT-L mice induced CD8+ T-cell responses 
to HCMV that are immunoprevalent in human infection, BLT-L 
donor tissue was HLA-typed (Supplementary Table 3) and reac-
tivity to HCMV pentamers examined. HCMV infection induced 
classically HLA Ia-restricted HCMV pp65-specific CD8+ T  cells 
in the human lung implant as early as 12 d following HCMV TB40/E 
inoculation (Fig. 4c,d and Supplementary Table 4). The functional-
ity of these T cells was also examined by HCMV pentamer over-
lay of cells (mononuclear cells pooled from the liver of three mice, 
cohort B) stimulated with mitogen (Fig. 4d). All HCMV pentamer-
reactive CD8+ T cells (red events, Fig. 4d right panel) were functional, 
producing the antiviral cytokine IFN-γ or both IFN-γ and the lytic 
granule marker CD107a.
Additional functional studies were performed using either 
ex vivo IFN-γ enzyme-linked immunospot (ELISpot) assays or 
intracellular cytokine staining (ICS), in which irradiated autologous 
B-cell lines were used to present HCMV peptide epitopes or peptide 
pools (HCMV pp65 or IE1) to tissue cells (Supplementary Table 4).
Here, we compared TB40/E and AD169 infection. Similar to TB40/E, 
AD169 induced T-cell responses to HLA-A and HLA-B pp65 peptide 
epitopes in BLT-L mice (Fig. 4e and Supplementary Table 5). Both
strains also consistently induced T-cell responses to HCMV IE1 as
early as 14 d postexposure (Fig. 4f,g and Supplementary Table 5).
IE1 is an immunoprevalent HCMV protein not found in virions but 
expressed after infection42. The detection of IE1-specific responses
is consistent with the in vivo lytic replication of HCMV observed in 
Fig. 4a. HCMV-specific T-cell responses were detected in the human 
lung implant of BLT-L mice and systemically (liver and mouse lung) 
(Fig. 4c–h) and were maintained for up to 125 d (last time point
analyzed) (Fig. 4h and Supplementary Table 4). Full details of T-cell 
reactivity are provided in Supplementary Table 4.
Our data demonstrating IE1-specific T-cell responses in BLT-L 
mice and a progressive decline in TB40/E-luciferase activity indi-
cate that these mice were productively infected with HCMV, but, 
unlike LoM (Figs. 2k–n and 4a and Supplementary Fig. 9), virus 
replication was controlled. HCMV DNA was readily detected in the 
human lung implants of all BLT-L mice analyzed <14 d postexposure 
(Supplementary Table 6). However, consistent with the immune-
mediated virological control observed in BLT-L mice (Fig. 4a), only 
55% of human lung implants analyzed between 14–34 d postexpo-
sure, and none of the human lung implants analyzed after 34 d postex-
posure, had detectable levels of viral DNA (Supplementary Table 6). 
HCMV DNA was rarely detected in other tissues analyzed (12 of 
135) (Supplementary Table 6), suggesting that HCMV dissemina-
tion to peripheral tissues was limited and/or replication controlled.
Re-exposure boosts antibody and T-cell responses to HCMV. To 
mimic the ongoing antigenic exposure that occurs during chronic 
HCMV infection, we investigated the effect of repeated HCMV 
exposure on host immune responses. Mice were inoculated with 
3–4 doses of HCMV TB40/E or AD169.
Over 90% (22 of 24) of mice had detectable HCMV-specific IgM 
following repeated (3–4 times) HCMV exposure, regardless of the 
infecting HCMV strain (Fig. 5a). HCMV-specific IgG was detected in 
~73% (16 of 22) of re-exposed BLT-L mice (Fig. 5b), demonstrating 
efficient class switching. Plasma samples collected from BLT-L mice 
repeatedly exposed to TB40/E and with detectable HCMV-specific 
IgM and IgG possessed neutralizing activity, reducing HCMV infec-
tion in vitro by up to 91% (Supplementary Fig. 10). The time from 
first HCMV exposure to antibody testing differed between singly 
or multiply exposed mice (1 dose: mean 48 d postexposure, range 
12–125 d; and 3–4 doses: mean 77 d postexposure, range 42–120 d). 
We cannot therefore exclude that time, in addition to repeated anti-
gen exposure, contributed to class switching. However, TB40/E failed 
to induce HCMV-specific IgG 125 d after a single exposure (Fig. 5b 
and Supplementary Table 4), despite the presence of a detectable 
HCMV-specific CD8+ T-cell response (Fig. 4h).
HCMV infection induces robust and sustained CD4+ T-cell 
responses50. In BLT-L mice inoculated once with HCMV, we were 
unable to detect HCMV-specific CD4+ T-cell responses by ICS 
(data not shown). However, following repeated HCMV expo-
sure, IE1-specific CD4+ T-cell cytokine responses were detected 
in the human lung implant and liver of BLT-L mice, suggest-
ing that repeated antigen exposure induced or augmented anti-
gen-specific CD4+ T-cell responses (Fig. 5c). IE1-specific CD8+ 
T-cell responses measured by ICS were detected more frequently
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Fig. 5 | HCMV re-exposure further promotes antibody induction and class switching and boosts HCMV-specific t-cell responses in BLt-L mice.  
a,b, HCMV-specific IgM (a) and IgG (b) in naïve BLT-L mice (n = 5) and following single or 3–4 exposures to HCMV TB40/E (IgM n = 15 single and  
11 re-exposed mice, IgG n = 4 single and 11 re-exposed mice) or AD169 (IgM n = 8 single and 13 re-exposed mice, IgG n = 4 single and 11 re-exposed 
mice). Negative (open diamonds) and positive (filled diamonds) standards (STD). Shown is the mean of three technical replicates per mouse. Dashed 
line, threshold for seropositivity defined from naïve controls. c, HCMV re-exposure induced IE1-specific TNF-α/IFN-γ double positive CD4+ T cells at the 
site of inoculation, the human lung implant and systemically in the liver. Contour plots exampling HCMV-IE1-specific CD8+ T-cell IFN-γ production and 
CD107a degranulation in a BLT-L mouse. d, CD8+ T cells were isolated from combined tissues of TB40/E (top panels representative of measurements 
in 4 independent BLT-L mice) or AD169 (bottom panels representative of measurements in 11 independent BLT-L mice) exposed mice, stimulated and 
then assessed using ICS. e, Summary graph showing background subtracted IE1-specific CD8+ T-cell responses (IFN-γ production) in mice receiving 
repeated inoculations of TB40/E or AD169. Filled symbols show positive responses and open symbols indicate negative responses. TB40/E open squares 
and circles represent mice in cohorts D and F, respectively; AD169 open squares and circles represent mice in cohorts D and E, respectively. f, Repeated 
TB40/E (top panels representative of measurements in four independent BLT-L mice) and AD169 (bottom panels representative of measurements in four 
independent BLT-L mice) exposure induced high frequencies of HCMV-specific CD8+ T cells as determined by pentamer reactivity. Full details of immune 
reactivity for each multiple exposed BLT-L mouse are indicated in Supplementary Tables 7 and 8.
BLT-L mice (Fischer’s exact, two-tailed P = 0.039) (Fig. 5d,e and 
Supplementary Tables 4, 7 and 8). Repeated HCMV exposure 
also induced stronger HCMV-specific CD8+ T-cell responses 
across tissues (Figs. 4h and 5d–f), producing T-cell responses 
consistent with those reported in human HCMV infection51–54. 
Increases in pentamer reactivity were also observed. Classically 
restricted HCMV-specific CD8+ T cells in repeat exposure BLT-L 
mice approached 2% of all CD8+ T cells (Fig. 5f), between 4- and 
15-fold greater than pentamer frequencies observed following
a single exposure (Fig. 4c,d and data not shown). Full details of
immune reactivity following repeated HCMV inoculation are
provided in Supplementary Tables 7 and 8.
Although BLT-L mice were exposed to multiple doses of TB40/E 
or AD169, HCMV DNA was only detected in the human lung 
implants of 9 of 18 mice analyzed (2 TB40/E- and 7 AD169-exposed 
BLT-L mice) (Supplementary Tables 9 and 10). HCMV DNA was 
rarely detected in tissues other than the human lung implants (3 of 
108 tissues analyzed) and was not detected in PB (Supplementary 
Tables 9 and 10), suggesting strong immune control of HCMV 
replication in vivo.
Discussion
To extend the breadth of human pathogens that can be studied using 
humanized mice, we validated two models, LoM and BLT-L mice, 
which provide human lung tissue as an in  vivo target for human 
pathogens either without (LoM) or with (BLT-L mice) an autolo-
gous systemic human immune system. The engraftment levels of 
human immune cell types in BLT-L mice are similar to previously 
reported BLT mice55–57. The subcutaneously implanted human lung 
tissue expands and develops into lung implants containing human 
epithelial, endothelial and mesenchymal cells and a vasculature of 
human origin. Located just underneath the skin, the lung implants 
can be readily accessed and imaged.
Using LoM, we demonstrated that the human lung implants 
are susceptible to five diverse emerging and clinically relevant 
human pathogens (MERS-CoV, ZIKV, mycobacteria, RSV and 
HCMV) without further engineering of the pathogens or the host. 
However, it is possible that a respiring lung will have different host 
gene expression profiles, which could alter the replication condi-
tions of some pathogens. We next demonstrated that pre-exposure 
prophylaxis with GCV can effectively control HCMV replication 
in LoM and performed an in vivo transcriptome analysis of lytic 
HCMV infection. In the future, transcriptome analyses of the 
pathogen and host may identify new drug targets and host factors 
that modulate infection.
HCMV infection in BLT-L mice produced acute virus kinetics 
that reflected lytic replication, consistent with those reported in 
humans. With the onset of adaptive humoral and T-cell responses, 
HCMV replication in BLT-L mice declined to background levels. 
Whereas HCMV DNA was detected in all exposed LoM, HCMV 
DNA was only detected in BLT-L mice during the first 2 weeks 
postinfection, consistent with the strong virological immune 
control observed. CD8+ T-cell responses were detectable in the 
lung implant as early as 12 d postinoculation to multiple epitopes 
including the IE1 and pp65 proteins, which are targeted in 50% 
of human patients58. HCMV-specific T  cells were detected sys-
temically in the liver and mouse lung. HCMV-specific CD8+ 
T-cell responses were detected up to 125 d following inoculation.
The induction of a systemic antigen-specific immune response
in BLT-L mice, combined with our data demonstrating the pro-
duction of human cytokines/chemokines following ex vivo mito-
gen stimulation of human immune cells isolated from the lung
implants, demonstrates the functionality of the human immune
cells that repopulate the lung implants.
Mimicking the ongoing antigenic exposure that occurs during 
chronic HCMV infection, multiple exposures to HCMV resulted 
in a more robust HCMV-specific antibody and T-cell response in 
BLT-L mice. We readily detected HCMV-specific IgG in BLT-L mice 
re-exposed to TB40/E or AD169, suggesting that repeat antigen 
stimulation facilitates human IgG class switching. Multiple HCMV 
exposures also induced a robust HCMV-specific T-cell response. 
Natural HCMV infection in humans elicits a life-long CD4+ and 
CD8+ T-cell response and very high reactivity (80–100%) to IE1 and 
pp65 proteins58,59. We readily observed IE1-specific CD4+ T cells in 
multiple tissues of BLT-L mice repeatedly exposed to HCMV. The 
magnitude of the HCMV-specific CD8+ T-cell response was also 
increased in BLT-L mice exposed to multiple doses of HCMV and 
reached levels comparable to humans52–54,60,61. The fact that repeated 
exposure can be used to broaden the immunoprevalence of T-cell 
responses in BLT-L mice suggests that the model might be useful in 
vaccine testing.
We did not observe an HCMV-specific CD8+ T-cell response 
or HCMV-specific IgG in cohort F of BLT-L mice, despite mul-
tiple exposures to TB40/E. This cohort (F) was homozygous 
across all class Ia and II alleles (Supplementary Table 3). HCMV 
induced low levels of IgM but no class switching was observed 
(Fig. 5a,b, square symbols). Despite a 111–120 d follow-up (post-
first HCMV exposure), no IE1-specific T-cell IFN-γ+/CD107a+ 
responses were detected (Fig. 5e and Supplementary Table 7). 
T  cells and myeloid dendritic cells (mDCs) in this cohort were 
functional; specifically, mitogenic stimulation of T cells induced 
potent cytokine production and degranulation, and autologous 
mDCs induced a mixed-lymphocyte reaction when cocultured 
with allogeneic peripheral blood mononuclear cells (data not 
shown). These results suggest that a limited repertoire of HLA-
presented viral peptides impedes the generation of antigen-spe-
cific adaptive immune response in vivo.
BLT-L mice generate antigen-specific humoral and cell-medi-
ated immune responses that control pathogen replication in vivo. 
These results validate BLT-L mice as an in vivo platform to study 
the replication, pathogenesis and immunogenicity of human patho-
gens in the context of a functional systemic human immune system. 
In this regard, BLT-L mice would support the type of direct, system-
atic and sophisticated in vivo experimentation that is characteristic 
of rodent models but cannot be performed in humans. Our results 
also support BLT-L mice as a model for the in vivo evaluation of 
human immune therapies, including vaccines, especially for dis-
eases with a strict species tropism.
In summary, we have developed two humanized mouse models 
that support infection and replication of important human viral 
and bacterial pathogens. LoM and BLT-L mice could be used to 
study other human pathogens that target the lung (for example, 
enterovirus D68, adenovirus type 7, influenza virus, rhinovirus 
and metapneumovirus), accelerating the in vivo testing of preven-
tative and therapeutic approaches for these agents. Our analysis of 
implant vascularization using 3D ultrasound acoustic angiography, 
a noninvasive technique to visualize microvasculature, also sug-
gests that this technology can be used for monitoring angiogen-
esis and vascularization in other systems. Our results also suggest 
that developing additional in  vivo humanized mouse models for 
human pathogens with tropism for other tissues might be possible 
and might enhance the precision of humanized mouse models for 
biomedical research.
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A.W. inoculated mice with HCMV; collected and processed PB and tissues from 
HCMV-exposed mice; performed experiments with PB and tissue cells and analyzed 
the data; performed the flow cytometric and IHC analysis of naïve LoM and BLT-L 
mice; performed the human cytokine/chemokine analysis; inoculated mice with BCG 
and collected tissues from BCG-exposed mice; conceived and designed experiments; 
contributed to data interpretation, data presentation and manuscript writing; and 
conceived, designed and coordinated the study, the preparation of the manuscript 
and its revision. C.D. inoculated mice with HCMV; performed the GCV experiment, 
the in vivo imaging of mice and neutralization assay; collected and processed PB and 
tissues from HCMV-exposed mice; performed experiments with PB and tissue cells and 
analyzed the data; performed the human cytokine/chemokine analysis; inoculated mice 
with RSV; and collected and processed tissues and measured RSV-GFP expression by 
flow cytometry. M.A.F. performed experiments with PB and tissue cells and analyzed 
the data; standardized, designed, performed and analyzed immunological assays; and 
contributed to data interpretation, data presentation and manuscript writing. E.M.L. 
LoM were fixed in 10% formalin for >7 d at 4 °C, embedded in paraffin, sectioned 
(5 µm) and stained with MERS-CoV nucleocapsid polyclonal antibody (Life 
Sciences Reporting Summary). Tissue sections were also stained with appropriate 
isotype-negative control antibodies. Tissue sections for immunohistochemistry 
were imaged on a Nikon Eclipse Ci microscope using Nikon Elements BR software 
(version 4.30.01) with a Nikon Digital Sight DS-Fi2 camera and brightness and 
contrast were adjusted on whole images in Adobe Photoshop (CS6). Tissue sections 
for immunofluorescence were imaged on an Olympus BX61 upright wide-field 
microscope using Improvision’s Velocity software (version X) with a Hammatuse 
ORCA RC camera. Brightness and contrast were adjusted on whole images using 
ImageJ software (version 1.51C). In Fig. 2b,d,h,m, pseudocoloring was used to 
depict MERS-CoV, ZIKV, RSV and HCMV antigens in green and human cell 
types in magenta. In Figs. 1i,j and 2i and Supplementary Fig. 1b, where red/green 
fluorescent images were originally captured, the red fluorescent signal was digitally 
altered to improve visualization by color-blind readers by adjusting the red channel 
hue by −45 using Adobe Photoshop (CS6).
Analysis of human immune cell reconstitution. Human immune cell 
reconstitution in the PB and tissues of BLT-L mice were analyzed by flow 
cytometry. Mononuclear cells (MNCs) were isolated from tissues collected from 
BLT-L mice by passage through a cell strainer and red blood cell lysis as previously 
described13,14,62–64. The human lung implants, mouse lung, liver and female 
reproductive tract were enzymatically digested before passing tissue through a cell 
strainer. Liver and mouse lung MNCs were purified with a Percoll gradient. MNCs 
were isolated from the gastrointestinal tract (small and large intestines) lamina 
propria layer with an enzymatic digest as previously described. Before antibody 
(Life Sciences Reporting Summary) incubation Ig-binding sites were blocked. The 
antibody panels were as follows: CD45-APC, CD19-PE, CD3-FITC and  
CD4-PerCP (panel 1); CD45-APC, CD19-PE-Cy7, CD33-PE, CD3-FITC,  
CD4-APC-H7 and CD8-PerCP (panel 2); CD45-APC, CD19-PE-Cy7, CD33-PE, 
CD3-FITC and CD8-APC-Cy7 (panel 3); CD45-V500, CD3-AlexaFlour 700 or 
APC-R700, CD4-BV605, CD8-APC-Cy7, CD45RO-FITC or negative control 
mouse IgG2ak-FITC, CD69-PE or negative control mouse IgG1k, CCR7-PE-Cy7  
or negative control rat IgG2aak, HLA-DR-PerCP or negative control mouse 
IgG2ak-PerCP, and CD25-APC or negative control mouse IgG1k-APC (panel 4);  
and CD45-V500, CD19-PE-Cy7, CD3-AlexaFlour 700 or APC-R700, CD4-APC-H7, 
CD8-FITC, CD45RA-Pacific Blue or negative control mouse IgG1ak-Pacific 
Blue, CD27-PE or negative control mouse IgG1k-PE, HLA-DR-PerCP or negative 
control mouse IgG2ak-PerCP, and CD38-APC or negative control mouse IgG1k-
APC (panel 5). Following antibody incubation, PB was treated with 1X BD 
FACS lysing solution (BD Biosciences) to remove red blood cells. Samples were 
then washed and fixed with PFA. Data were acquired on a BD LSRFortessa or 
FACSCanto instrument and analyzed with FACSDiva software (version 6.1.3).
Analysis of human cytokine/chemokine production. MNCs were isolated from 
BLT-L mouse (n = 6 mice and 12 lung implants, data represent two experiments) 
human lung implants. Human lung implants were enzymatically digested 
before passing tissue through a cell strainer and MNCs were purified with a 
Percoll gradient. MNCs were pooled from the lung implants of 3 mice (n = 6 
lung implants) and cultured (7.8 × 105 cells per well of a 48-well plate) for 4 h in 
RPMI supplemented with 10% FBS and 1% penicillin/streptomycin (untreated 
control, 1 well per experiment) or media supplemented with PMA (25 ng ml−1)/
Ionomycin (250 ng ml−1) (1 well experiment 1, and 2 wells experiment 2) or with LPS 
(100 ng ml−1, E. coli O55:B5, Sigma) (1 well per experiment). Cell culture supernatant 
was collected at 4 h. Cells were also isolated from the human lung implant of LoM 
(n = 1 mouse, 2 human lung implants, represents one experiment) following a 
24 h enzymatic digest (1% Protease XIV/0.01% DNase solution diluted 1:19 in F12 
medium supplemented with amphotericin and gentamicin) at 4 °C. Cells (1 × 106 
cells per well) were cultured overnight in bronchial epithelial growth medium 
(BEGM)67 supplemented with 10% FBS in wells of a collagen-coated 48-well plate 
(5.6 μg cm−2 human placental collagen type IV). Wells were washed to remove 
nonadherent cells and then cells cultured in BEGM + 10% FBS medium alone 
(untreated control) or supplemented with LPS (100 ng ml−1, E. coli O55:B5, Sigma) 
(3 wells per condition/lung implant). Cell culture supernatant was collected at 24 h. 
Plasma was isolated from PB collected from BLT-L mice (n = 10 mice, represents 
three experiments) 3 d before and 4 d post-HCMV-TB40/E (2.2 × 106 tissue culture 
infectious dose (TCID)50) inoculation into human lung implants. Human cytokine/
chemokine levels in cell culture supernatant and plasma were measured using 
a Milliplex MAP kit (Millipore no. HCYTMAG-60K-PX41, limit of detection: 
3.2 pg ml−1) on a Luminex MagPix instrument. Samples were run undiluted in 
singular wells. The following 41 human analytes were measured: Eotaxin/CCL11, 
FGF-2, Flt-3 ligand, Fractalkine, G-CSF, GM-CSF, GRO, IFN-α2, IFN-γ, IL-1α, 
IL-1β, IL-1rα, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p40), IL-12 
(p70), IL-13, IL-15, IL-17A, IP-10, MCP-1, MCP-3, MDC (CCL22), MIP-1α, MIP-
1β, PDGF-AA, PDGF-AB/BB, RANTES, sCD40L, TGF-α, TNF-α, TNF-β, VEGF 
and EGF. BEGM contains human EGF; therefore, EGF levels were not reported.
MERS-CoV production and analysis of infection. Stocks of the wild-type HCoV-
EMC/2012 of MERS-CoV (originally provided by Dr. Bart Haagmans, Erasmus 
Methods
Ethics statement. Animal studies were carried out according to protocols approved 
by the Institutional Use and Care Committee at the University of North Carolina-
Chapel Hill and in adherence to the National Institutes of Health Guide for the 
Care and Use of Laboratory Animals.
Generation of humanized mice. LoM were constructed by implanting two 
pieces (~2–4 mm3) of human fetal lung tissue (Advanced Bioscience Resources) 
subcutaneously into the back (right and left back or upper and lower back) of 
13–18-week-old male and female NOD.Cg-Prkdcscid ll2rgtm1Wjl/SzJ mice (NSG mice; 
The Jackson Laboratory), creating two separate human lung implants. Engraftment 
and expansion of the human lung implants was monitored by palpation. After 
12 weeks postimplantation, the lung implants are readily palpable under the skin 
of the mice and easy to manipulate for experiments. The lung implants persist for 
at least 12 months postimplantation (last time point analyzed). BLT-L mice were 
constructed by implanting a sandwich of human fetal thymus-liver-thymus tissue 
(Advanced Bioscience Resources) under the kidney capsule of irradiated (200 rad) 
10–15-week-old male and female NSG mice. Two pieces of autologous human lung 
tissue (~2–4 mm3) were implanted subcutaneously into the right and left back. 
Following tissue implantation, animals received a bone marrow transplant (via tail-
vein injection) of autologous liver-derived human CD34+ hematopoietic stem cells. 
The non-CD34+ cell fraction was used for four-digit HLA typing at the HLA-A, 
B and C loci. Reconstitution of BLT-L mice with human hematopoietic cells was 
monitored longitudinally by flow cytometry as previously described13,14,62–64. Mice 
were maintained by the Division of Comparative Medicine at the University of 
North Carolina-Chapel Hill.
Ultrasound imaging. Two forms of 3D ultrasound imaging using Vevo 770 
(version V3.0.0, VisualSonics) acquisition software were performed: B-mode, 
which is sensitive to different tissue types, and acoustic angiography, which is 
sensitive to microvasculature. B-mode imaging was used to assess implant volume, 
while acoustic angiography was performed to visualize implant vasculature. 
Acoustic angiography has been described in detail previously35,36. For imaging, 
LoM (n = 6 mice, 12 human lung implants, 24–35 weeks postsurgery) were 
anesthetized with vaporized isoflurane (maintained at 2.0–2.5%), the animal’s side 
and back were depilated with a hair-removal cream (Nair) and the ultrasound 
transducer was coupled to the skin with gel. For acoustic angiography imaging, 
a microbubble contrast agent diluted in saline was administered intravenously 
through a tail-vein catheter. The lipid-shelled, perfluorocarbon core microbubble 
contrast agent used here is standard for ultrasound imaging and has been 
described in this application previously65. Rendering in 3D was performed with 
Slicer (version 4.8.1).
Human lung implant volume measurement. All image processing and analyses 
were performed in MATLAB R2017b (version 9.3.0.713579, Mathworks). Implant 
volume was measured from 3D B-mode ultrasound images as follows. First, the 
center slice of the implant was identified in all three orthogonal planes, and the 
dimensions of the implant were measured in each central slice, resulting in two 
measurements of each dimension. The two independent measurements were 
then averaged to obtain the three orthogonal dimensions (that is, diameters) of 
the implant. Implant volume was approximated as that of an ellipsoid of the same 
size, given by V ¼ 43 πabc
I
, where a, b and c are equal to one-half of the orthogonal 
dimensions measured.
Immunohistochemical analysis. Immunohistochemical analyses were performed 
as previously described14,63,64,66. Briefly, human lung tissue and tissues collected 
from NSG, LoM and BLT-L mice were fixed in 4% paraformaldehyde (PFA) or 10% 
formalin, paraffin embedded and cut into 5 µm sections. Before primary antibody 
incubation, antigen retrieval was performed and Ig-binding sites and endogenous 
peroxidase activity blocked. Tissue sections were developed using the MACH-3 
polymer system (BioCare Medical) and 3,3′-diaminobenzidine (DAB) (Vector 
Laboratories), counterstained with hematoxylin and mounted. Immunofluorescence 
staining was also performed on 4% PFA or formalin-fixed, paraffin-embedded tissue 
sections. Following antigen retrieval and blocking with 5% serum (corresponding to 
the secondary antibody’s host species), 0.1% Triton X-100 and 50% Rodent M block 
(BioCare Medical) in PBS, tissue sections were incubated with primary antibodies 
overnight at 4 °C. Tissue sections were then stained with fluorescent conjugated 
secondary antibodies followed by DAPI and then mounted. Primary antibodies 
were directed against human epithelial cells (cytokeratin 19), endothelial cells 
(CD34), mesenchymal cells (vimentin), hematopoietic cells (CD45), macrophages 
(CD68), dendritic cells (CD11c), NK cells/NK T cells (CD56), B cells (CD20), 
T cells (CD3), CD4+ cells (CD4) and CD8+ cells (CD8) (Life Sciences Reporting 
Summary). Primary antibodies directed against mouse endothelial cells (mCD34), 
epithelial cells (mcytokeratin 19) and hematopoietic cells (mCD45) were used to 
distinguish the presence of mouse cells (Life Sciences Reporting Summary). Primary 
antibodies directed against HCMV glycoprotein B, IE, early and late proteins were 
used to detect HCMV-positive cells (Life Sciences Reporting Summary). Tissue 
sections were stained with an anti-ZIKV NS2B antibody to detect ZIKV-infected 
cells. Small pieces of human lung implant tissue collected from MERS-CoV-infected 
two GVC doses. Untreated LoM (n = 5 mice, 7 human lung implants) inoculated 
with HCMV TB40/E expressing luciferase (4.25 × 105 TCID50) served as a control. 
Luciferase expression was measured on anesthetized mice with an IVIS Lumina 
Optical System following intraperitoneal injection of D-Luciferin (15 mg kg−1) on 
days 4, 11, 14, 21 and 25 postexposure. For the AD169 time course experiment 
in LoM, human lung implants were collected at days 4 (n = 2 mice, 3 human lung 
implants), 7 (n = 2 mice, 4 human lung organoids), 14 (n = 2 mice, 4 human lung 
implants), 21 (n = 2 mice, 4 human lung implants) and 28 (n = 2 mice, 4 human 
lung implants) postexposure and data represent one experiment. To evaluate 
HCMV replication over time in human lung implants, HCMV TB40/E expressing 
luciferase (4.25 × 105 TCID50)45 was inoculated into the human lung implants of 
human donor matched LoM (n = 3 mice, 6 human lung implants) and BLT-L mice 
(n = 3 mice, 6 human lung implants). Luciferase expression was measured on 
anesthetized mice with an IVIS Lumina Optical System following intraperitoneal 
injection of D-Luciferin (15 mg kg−1) on days 4, 7, 11 and 14 and weeks 4 and 5 
following HCMV exposure. Baseline luminescence in human lung implants was 
determined in LoM and BLT-L mice before HCMV exposure. Data represent one 
experiment in LoM and BLT-L mice. To evaluate the HCMV-specific immune 
response after multiple virus doses, BLT-L mice received three (administered 
1 month and then 2 weeks apart) or four (administered 2 weeks apart) inoculations 
of HCMV TB40/E or AD169. Data represent five experiments. PB and tissues were 
collected from LoM and BLT-L mice and processed as described previously and 
above. In Fig. 2k, human lung implant cells isolated from TB40/E-infected LoM 
were also Percolled. HCMV DNA levels in PB and tissue cells were measured by 
real-time PCR analysis as previously described73.
HCMV transcriptome analysis. Total RNA was extracted from human lung 
implants collected from HCMV TB40/E-infected LoM using Trizol following  
tissue homogenization and combined. Data represent one experiment. Ribosomal 
RNA was depleted using RiboMinus (Thermo Fisher). (ds)cDNA was generated 
from rRNA-depleted total RNA using the SMARTer PCR cDNA synthesis  
kit (Takara). Viral-specific (ds)cDNA was then captured using custom-designed 
biotinylated probes spanning both strands of the entire HCMV genome  
(Agilent). After extensive washing, the bound (ds)cDNA was eluted from the 
capture probes, and next generation sequencing libraries were generated from  
the eluted (ds)cDNA using the Nextera XT trans-fragmentation kit (Illumina).  
The resulting library was sequenced on an Illumina HiSeq 2500 using 2 × 100 base 
pair paired-end reads. High-quality reads were aligned to the HCMV genome,  
and viral expression was quantified in reads per kilobase per million using Cuffdiff 
(Cufflinks, version 2.2.1).
Detection of IgM and IgG antibodies to HCMV. Antibodies to HCMV in plasma 
were measured using either an HCMV IgM or IgG enzyme immunoassay test kit 
(Genway). HCMV IgM or IgG Index = average optical density of triplicate samples/
(calibrator optical density × lot-specific Calibrator Factor), as per manufacturer’s 
protocol. Randomly selected samples were re-run to assess intra-assay variability. 
All tests showed low inter- and intra-assay variability (<10% coefficient of 
variation). A seropositive sample was designated as having either an HCMV IgM 
or IgG index > measured index from naïve BLT-L mice (n = 5). To analyze the 
HCMV neutralizing activity in plasma of HCMV-exposed BLT-L mice, the plasma 
of a naïve BLT-L mouse (n = 1) and BLT-L mice exposed repeatedly to TB40/E  
(3–4 times, n = 6 mice) was heated at 56 °C for 15–20 min then diluted 1:60 in 
DMEM/F12 medium supplemented with 10% FBS (heat-inactivated) and 1% 
penicillin/streptomycin. Diluted plasma was incubated with HCMV-TB40/E-RFP 
for 1 h at 37 °C. The virus mixture was added to ARPE-19 cells (multiplicity of 
infection 5) in quadruplicate wells of a 24-well plate and incubated for 2 h at 37 °C 
at which time virus containing medium was removed and fresh medium added. 
After 72 h, cells were fixed, stained with DAPI and the number of RFP+ cells 
counted. Data represent one in vitro infection experiment.
Human antigen-presenting cell (APC) production. Autologous human 
B-lymphoblastoid cell lines (BLCLs) or mDCs were generated from each human 
tissue donor analyzed (eight donors total) and used as APCs in ELISpot and ICS 
assays. BLCLs were derived from the human fetal liver CD34-negative fraction or 
from human CD19+ cells positively selected from BLT-L tissue cells using CD19 
microbeads (Miltenyi), following the manufacturer’s instructions. Cells were 
infected with EBV B95-8 overnight and maintained at 37 °C until transformation 
(8–10 weeks later). BLCLs were propagated in RPMI 1640 with 10% FBS. mDCs 
were generated from human fetal liver-derived CD34+ cells magnetically selected 
using CD34 microbeads (Miltenyi). Purified CD34+ cells were plated at a 
concentration of 1 × 106 cells per ml in IMDM medium supplemented with 10% 
FBS, 100 ng ml−1 GM-CSF, 2.5 ng ml−1 TNF-α, 50 ng ml−1 Flt-3L, 2.5 ng ml−1 SCF 
and 10 ng ml−1 IL-4 (R&D Systems). Medium was refreshed every 3 d. Maturation 
of DCs was initiated 3 d before planned T-cell assays using IMDM supplemented 
with 10% FBS, 800 U ml−1 GM-CSF, 10 ng ml−1 TNF-α, 1 μg ml−1 PEG-2, 10 ng ml−1 
IL-1β, 400 U ml−1 IL-4 and 100 ng ml−1 IL-6 (R&D Systems). Autologous BLCLs 
(CD19-PerCP positive) or mDCs (CD11c-PE positive) were phenotyped by flow 
cytometry using the following antibodies: pan-HLA-I Class-Pacific Blue, HLA-
E-PE and HLA-DR-PE-Cy7; or CD80-PE-Cy7, CD83-APC and CD86-PE-Cy7, 
Medical Center, Rotterdam, the Netherlands at passage 8) were prepared and 
virus titers determined on Vero CCL81 cells (American Type Culture Collection) 
under Biosafety Level 3 conditions as previously described1. MERS-CoV (104 or 
105 PFU per human lung implant) was inoculated in the human lung implants of 
anesthetized LoM via direct injection (50 µl volume) and human lung implants 
collected at 48 h postinfection (104 PFU: n = 2 mice, 4 human lung implants and 
data represent one experiment, 105 PFU: n = 4 mice, 8 human lung implants and 
data represent two experiments). To determine tissue MERS-CoV titers, pieces of 
human lung implant were weighed, homogenized and then stored at −80 °C.
ZIKV production and analysis of infection. Stocks of ZIKV strain H/PF/2013 
were prepared on Vero CCL81 cells (American Type Culture Collection). Virus 
titers were determined by quantifying the number of ZIKV RNA copies with real-
time PCR (3,208 ZIKV RNA copies per FFU based on real-time PCR analysis of 
ZIKV stocks titered on Vero CCL81 cells as previously described68). The human 
lung implants of LoM were injected with 104 or 103 FFU ZIKV (n = 2 LoM, 
4 human lung implants, per dose and data represent one experiment) (100 µl 
volume per implant). Mice were necropsied 48 h postinoculation. Human lung 
implants were processed into a single-cell suspension as described above. Cell-
associated ZIKV RNA levels were measured using a quantitative real-time PCR 
assay using TaqMan RNA-to-CT 1-step kit (Applied Biosystems). The sequences 
of the forward and reverse primers and the TaqMan probe for PCR amplification 
and detection of ZIKV RNA were: 5′-CCGCTGCCCAACACAAG-3′, 
5′-CCACTAACGTTCTTTTGCAGACAT-3′ and 5′-FAM-AGCCTACCT/ZEN/
TGACAAGCAGTCAGACACACTCAA-Q-3′, respectively69.
BCG production and analysis of infection. M. bovis BCG Pasteur was grown at 
37 °C in liquid Middlebrook 7H9 medium supplemented with 0.05% Tween 80, 
0.5% glycerol and 1X albumin-dextrose-saline (>0.5% bovine serum albumin, 
0.2% glucose, 0.85% NaCl). The human lung implants of anesthetized LoM were 
injected with 4 × 104 or 4 × 102 c.f.u. BCG (n = 3 LoM, 3 human lung implants, per 
dose and data represent one experiment) (100 µl volume per lung implant). Mice 
were necropsied 28 d postexposure. At necropsy, one-half of each human lung 
implant was homogenized in PBS supplemented with 0.05% Tween 80, 100 ng ml−1 
cycloheximide and 50 μg ml−1 carbenicillin. The diluted homogenate was then 
plated onto 7H10-albumin-dextrose-saline-glycerol plates with 10 mg ml−1 
cycloheximide for c.f.u. enumeration. The total number of c.f.u. per human lung 
implant was calculated by multiplying the number of c.f.u. × 2.To visualize BCG, a 
LoM injected with 105 c.f.u. BCG via intra-human lung injection (100 µl volume) 
was necropsied 28 d postexposure and small pieces of human lung implant tissue 
were fixed in 4% PFA, paraffin embedded and sectioned (5 µm). Ziehl–Neelsen 
acid-fast staining was performed with carbol fuchsin and methylene blue. Tissue 
sections were imaged on an Olympus BX61 microscope with a RETIGA 4000R 
camera and brightness and contrast adjusted in Adobe Photoshop (CS6).
RSV production and analysis of infection. Recombinant RSV strain A2 
expressing GFP has been previously described70. RSV (2.5 × 105 tissue culture 
infectious units per human lung implant) was directly injected (100 µl volume) into 
the human lung implants of anesthetized LoM (n = 3 mice, 6 human lung implants 
and data represent two experiments). At necropsy (4 d postexposure), human lung 
implants were collected, enzymatically digested and passed through a cell strainer. 
RSV infection and replication were evaluated by measuring GFP expression 
with flow cytometry. Data were collected on a BD LSRFortessa instrument and 
analyzed with BD FACSDiva software (version 6.1.3). For immunofluorescence, 
paraffin-embedded tissue sections were probed with an anti-RSV antibody and 
an anti-cytokeratin 19 antibody or anti-β-tubulin IV antibody (Life Sciences 
Reporting Summary) to detect cilia of ciliated cells. Club cells were detected with 
an anti-CC10 antibody. Alcian-blue periodic acid-Schiff (AB-PAS) staining was 
performed to analyzed mucus production in human lung implants of naive control 
and RSV-infected LoM. Sections were imaged on an Olympus BX61 upright wide-
field microscope with a Hammatuse ORCA RC camera, an Olympus VS120 virtual 
slide scanning system with an Allied Vision Pike 5 CCD progressive scan camera 
or a Leica DM IRB epifluorescent microscope with a Q-Imaging Retiga Camera. 
Image acquisition was performed using Improvision’s Volocity (version 6.3) or 
Q-Imaging Q Capture software (version 2.81) and brightness/contrast adjusted on 
whole images using ImageJ software (version 1.51C).
HCMV production and infection of mice. Anesthetized LoM and BLT-L mice 
were exposed to HCMV by direct injection of HCMV TB40/E (4.25 × 105–6 × 106 
TCID50)45,71, ADrUL131 (2.4 × 105 TCID50)48 or AD169 (1.1–6 × 106 TCID50)72 
into the human lung implants. For the TB40/E time course experiment in 
LoM, human lung implants were collected at days 4 (n = 2 mice, 4 human lung 
implants), 7 (n = 2 mice, 4 human lung organoids), 14 (n = 3 mice, 5 human lung 
implants) and 21 (n = 2 mice, 3 human lung implants) postexposure and data 
represent one experiment. The TB40/E-infected human lung implant analyzed 
at 52 d postexposure in Fig. 2l represents an additional LoM. For the GCV pre-
exposure prophylaxis experiment, LoM (n = 3 mice, 6 human lung implants) were 
administered 100 mg kg−1 GCV daily for 17 d by intraperitoneal injection and 
inoculated with HCMV TB40/E expressing luciferase (4.25 × 105 TCID50)45 after 
measures are indicated in the figure legends and/or the Results. The exact value 
of n and what n stands for is in the figure legends and Methods details. Statistical 
analyses were performed in GraphPad Prism (version 6, 7 or 8) or R (version 3.4.4). 
No statistical methods were used to predetermine sample size. No randomization 
was used to determine how samples/animals were allocated to experimental groups 
or processed. Investigators were not blinded to group allocations or when assessing 
outcomes. For all statistical comparisons P < 0.05 was considered significant. All 
statistical tests were exact. A two-tailed Mann–Whitney test was used to compare 
luciferase activity in the human lung implants of LoM and BLT-L mice (Fig. 4a) 
and human immune cell levels in the mouse lung and human lung organoids of 
BLT-L mice (Supplementary Fig. 6). A two-tailed Fischer’s exact test was used to 
compare the incidence of HCMV-specific human IgM, IgG and CD8+ T cells in 
BLT-L mice exposed to one or multiple doses of HCMV (Figs. 4 and 5). Human 
cytokine and chemokine levels pre- and post-HCMV inoculation were compared 
with a two-tailed Wilcoxon matched-pairs signed rank test (Supplementary Fig. 8).
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Data availability
The data generated are available from corresponding authors on reasonable request.
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respectively (Life Sciences Reporting Summary). For APC irradiation and peptide 
pulsing, peptides were synthesized by Sigma-Genosys. Autologous BLCLs or 
matured mDCs were irradiated (5,000 rad), then pulsed for 60 min at 37 °C with 
either individual peptides (1–2.5 μg) or a pool of 69 overlapping peptides (12–18 
amino acids overlapping by 10 amino acids) spanning the CMV IE1 protein (0.5 μg 
of each peptide) for 60 min. Cells were then washed 3 times and counted before 
adding to T-cell assays. The individual peptides used in these studies include 
pp65(495-504) NLVPMVATV (A*02:01) and pp65(123-131) IPSINVHHY (B*35:01).
Ex vivo IFN-γ ELISpot assay. BLT-L tissue cells (3 × 105) were cocultured with 
peptide-pulsed, autologous BLCL in a 1:2 ratio in 200 μl for 18–20 h at 37 °C/5% 
CO2. Assays were performed in triplicate or quadruplicate. Tissue cells cocultured 
with mock-pulsed BLCLs served as a negative control and tissue cells cocultured 
with 50 ng ml−1 PMA + 500 ng ml−1 Ionomycin served as a positive control. ELISpot 
assay development and spot counting were performed as described previously74. 
ELISpot data were expressed as the mean spot forming units (SFU) per million 
CD3-positive T cells ± s.e.m. Positive T-cell responses were defined as those >50 
SFU per million CD3 T cells and ≥2× mean of negative control wells. While not 
a criterion for positivity, across all assays in all cohorts, the average of the mock-
pulsed BLCLs was 24.6 SFU per input cells, as detailed in Supplementary Table 5.
ICS. Peptide-pulsed autologous BLCL (2:1) or mDCs (1:10) were irradiated 
(5,000 rad) then combined with filtered (0.45 µm), total or CD8-microbead 
(Miltenyi)-selected tissue suspensions (minimum, 1 × 106 cells). Panels measured 
either (A) IFN-γ/CD107a or (B) IFN-γ/TNF-α. (A) For measurement of IFN-γ/
CD107a, cocultures were immediately stained with CD107a-APC, monensin 
added, then cultured for 6 h or overnight at 37 °C, 5% CO2. Next, cells were 
stained with Zombie NIR viability dye at room temperature for 20 min, then 
labeled with CD3-BV421; CD4-BV650; CD8-BV510; and PerCP-conjugated 
CD14, 16, 19 and 56 (dump channel) at room temperature for 15 min. Cells were 
fixed, permeabilized and stained intracellularly with IFN-γ-PE. (B) For detection 
of IFN-γ/TNF-α, monensin/Brefeldin A was added to cocultures, which were 
then incubated overnight at 37 °C, 5% CO2. The next day, cells were stained with 
Zombie NIR and lymphocyte markers described in (A) above. Cells were fixed, 
permeabilized and stained intracellularly with IFN-γ-FITC and TNFα-PE/Dazzyle 
594 (Life Sciences Reporting Summary). In all assays, fluorescence minus one 
controls were used for gating of CD107a, cytokine and CD8 reactive populations. 
For compensation, beads were used for all colors except Zombie. For Zombie, live 
and dead (heat-inactivated) cells were mixed and Zombie stained to generated 
positive and negative populations. All cells were acquired using an LSRFortessa 
flow cytometer and data analyzed with FlowJo software (version 10) (gating 
strategies illustrated in Supplementary Fig. 11a,b). T-cell responses were expressed 
as frequency of either CD8+ or CD4+ T-cell lymphocytes. An HCMV-specific T-cell 
response met the following criteria: >10,000 CD4- or CD8-positive events, >0.01% 
of CD4+ or CD8+ T cells, a minimum of 10 events in the IFN-γ /CD107a or IFN-γ /
TNF-α double-positive gate, 2 × no-peptide control.
Multimer reactivity. PE- or APC-conjugated pentamers (ProImmune) were used 
for staining of total or CD8-microbead- (Miltenyi Biotec) selected tissue (liver and/
or human lung) suspensions. In all assays, a minimum of 1 × 106 cells were used 
and cells were filtered (0.45 µm) before staining. Cells were stained with Zombie 2 
viability dye at room temperature for 20 min, followed by staining with pentamer 
(as per manufacturer’s instructions) at room temperature for 15 min. After washing, 
CD3-BV421; CD4-BV650; CD8-BV510; and PerCP-conjugated CD14, 16, 19 and 
56 (dump channel) were added and cells incubated on ice for 15 min. Cells were 
washed and fixed. All cells were acquired using an LSRFortessa flow cytometer 
and data analyzed with FlowJo software (version 10) (gating strategy illustrated in 
Supplementary Fig. 11c). A pentamer reactive population met the following criteria: 
>3,000 CD8-positive events, greater than 2 × control pentamer (HLA-mismatched, 
non-HCMV), greater than 0.01% of all CD8+ T cells, >10 events in the pentamer
gate and no evidence of nonspecific staining in non-CD8+ T-cell gates.
Statistical analyses. The statistical test used is indicated below and in the figure 
legends and/or the Results. The definition of center and dispersion and precision 
